Prosecution Insights
Last updated: November 04, 2026
Application No. 17/911,435

METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF

Non-Final OA §103§112
Filed
Sep 14, 2022
Priority
Mar 20, 2020 — PO 116179 +1 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Biosckin Molecular & Cell Therapies S A
OA Round
3 (Non-Final)
41%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1002 resolved
-19.1% vs TC avg
Strong +36% interview lift
Without
With
+35.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
75 currently pending
Career history
1091
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.8%
+22.8% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1002 resolved cases

Office Action

§103 §112
DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of t/e previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/9/2026 has been entered. Status of Application The Examiner acknowledges receipt of the amendments filed on 3/9/2026 wherein claims 10-12 have been cancelled. Claims 1-6 and 13-17 are presented for examination on the merits. The following rejections are made. Response to 1.132 Declaration The declaration under 37 CFR 1.132 filed 3/9/2026 is insufficient to overcome the rejection of claims 1-6 and 13-17 based upon de Silva Santos et al. (US 2011//0159057) in view of Gilchrist et al. (US 6692532) as set forth in the last Office action. The declaration states that Bonelike Poro (‘BLP’) (particles sizes of 2-5.6 mm) and Bonelike spherical granules (particle size of 250-500 um) are both suitable for use in providing mineralization of bone. The declaration states that BLP is not only sufficient for healing a defect that does not heal spontaneously but can outperform the biological gold standard in structural quality. The declaration also states that the spherical Bonelike granules are biologically effective, resorbable and permissive to bone growth, with performance enhanced by cellular loading. The data of the two products together demonstrate the superiority of the claimed granulometries over alternatives. While the declaration demonstrates that particles having granulometries overlapping (albeit separately) are useful in treating bone defects, it does not address the primary concern. The issue previously raised, and presently exists, is whether the claimed granulometries outperform the granulometries described by the prior art. The declaration does not address this. There is no question that the subgroups of the claimed particles can be used to treat bone defects and it would be reasonable to expect that their combination would similarly be useful. However, there is question as to whether the claimed granulometries provide a result which is outstanding when compared to the granulometries of the prior art. No resolving data on this concern has been provided. The granulometry profile of the present claims and that of Gilchrist is provided in the table below: Claimed granulometry Gilchrist granulometry Particle range: 150um -5.6 mm Particle range: 0.1-10 mm 10-20% of 150 -500 um --- (no range described) --- 30-50% of 500 um – 2 mm 44.5% 500 um - 2mm 40-60% of 2-5.6 mm 55.5% of 2-6 mm The particles of the claims and those of Gilchrist are substantially overlapping. Although the complete particle dimension profile is unclear for both the claimed invention and the prior art, it is noteworthy that both provide a very similar particle size range and possess overlapping granulometries for the 500um-2 mm and 2-5.6 (2-6mm) particles. Gilchrist is silent regarding the particles having a range between 150-500 um but as 500 um is on the upper limit of the claimed lower bound, it is reasonable to assume that this particle size could also contribute towards the range of 500um-2mm in which case Gilchrist would be substantially similar in granulometry profile. It is unclear to what extent, if any, the lower bound of the claimed granulometry range provides to the claimed materials bone repair properties and if such properties would distinguish the claimed profile apart from the profile taught by the prior art. It is generally the case that where the general conditions of a claim, such as here, are described by the prior art, it is not inventive to discover optimum or workable ranges by routine experimentation. The parsing out of particle size ranges from Gilchrist’s teaching is nothing more than routine optimization. Absent evidence that the range provides a critical outcome that would not be expected from the prior art, the range will be considered obvious. Response to Applicants’ Arguments Applicant’s amendments filed 3/9/2026 render moot the rejection of claims 10-12 made by the Examiner under 35 USC 101/112(b) (use claims). This rejection has been withdrawn. Applicant’s arguments filed 3/9/2026 regarding the rejection of claim 1 made by the Examiner under 35 USC 112(b) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 12/10/2025. In regards to the 112(b) rejection, Applicant asserts the following: The ranges “50 um to 600 um, from 200-600 um”, etc. are not exemplary disclosures but narrowing definitions. In response to A, a broad range followed by a narrow range that falls within the broad range is considered indefinite as it is unclear what range is limiting. That is, does the claim encompass 50 microns or 200 microns as a minimum dimension? Similar uncertainty is applied to the upper limits of the range. The claim is unclear as the claim does not distinctly identify what the dimensions of the invention are. Applicant’s arguments filed 3/9/2026 regarding the rejection of claim 1-6 and 13-17 made by the Examiner under 35 USC 103 over De Silva Santos et al. (US 2011/0159057) in view of Gilchrist et al. (US 6692532) have been fully considered but they are not found persuasive and is MAINTAINED for the reasons of record in the office action mailed on 12/10/2025. In regards to the 103 rejection, Applicant asserts the following: B) the submitted declaration exemplifies experimental data for sheep and dogs. The evidence in the declaration demonstrates that the granulometry claimed provides unexpected and advantageous results. In response to B, the declaration has been considered and responded to above under sections 4-8. The declaration/data therein does not allay the concerns that the claimed invention is derivative of the prior art as it merely reflects what was already known rather than demonstrate that the claimed invention provides an unexpected advantageous outcome. The prior art teaches that bioglass granules can be used to treat bone defects and that bioglass can be sized to dimensions similar to that claimed for the same purpose. Using the prior art as a framework to identify workable ranges similar to that claimed would have been within the ability of an ordinary skilled person. There is no question that bioglass particles can be used as a bone filler composition with excellent treatment results. The issue at present is whether the claimed granulometry provides an outcome that would have not been expected when compared to the granulometry described by the prior art. Given the overlap in particle dimensions, it is reasonable to expect similar outcomes. Evidence showing that the present range provides some level of criticality that is not observed in the prior art is required. The declaration appears to show that BLP and Bioglass spherical granules separately provide excellent results and so their combination would also provide excellent results. This finding is not unexpected but is instead what any ordinary person would expect. With this understanding, one of ordinary skill in the art would readily envisage combining BLP and Bioglass granules to form a third composition for use in treating bone defects.. Although this is not presently the basis for the rejection, but because the declaration appears to be taking the perspective that the two composition yield desired therapeutic outcomes, a combination of the two would yield a desired therapeutic outcome. This rationale is obvious. See MPEP 2144.06(I). Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-6 and 13-17 is/are rejected under 35 U.S.C. 103 as being unpatentable over De Silva Santos et al. (US 2011/0159057; of record) in view of Healy et al. (US 6692532; of record). De Silva Santos (Santos herein) describes a hydroxyapatite bioglass material that is useful in the field of medicine as a bone graft/regeneration material (see abstract) (see instant claims 5, 6 and 10-12). The bioglass is added to hydroxyapatite in a weight percentage of 10% or less relative to the hydroxyapatite (see [0024]) (see instant claims 1 and 14). The bioglass is a P2O5:CaO glass and contains a molar ratio for P2O5:CaO of 20:80 to 80:30 (see [0021]) (see instant claims 1 and 3). The bioglass is to be porous, having a global porosity of at least 20% and an intra- and interporosity of at least 20% by volume (see [0019]) (see instant claim 1) wherein the pores include micro- and macropores, the macropores having a diameter (i.e. size) of between greater than 50 microns (see instant claims 1 and 15) and the micropores having a size up to 5 microns (see [0019]) (see instant claims 1 and 16). See MPEP 2144.05(I) regarding the obviousness of overlapping ranges. Santos teaches that the bioglass may comprise 0-20 mol% of CaF2, Na2O and MgO (see [0021]) (se instant claims 2 and 3). The hydroxyapatite bioglass material may be a pellet (see title) or a powder (see [0026]) (see instant claim 4). Santos fails to teach the hydroxyapatite material as having a size ranging from 150 μm to 6 mm, wherein the granules have a distribution such that 10 to 20% of the particles are in a range of 150 to 500 μm, 30 to 50% of the particles are in a range of 500 μm to 2 mm, and 40 to 60% of the granulometry varies in a range of 2 to 5.6 mm. Gilchrist describes a bone glass formulation, the glass being similar in nature to that claimed, e.g. comprising P2O5, CaO, (see column 4, lines 37-45). The glass is to have a particle size of between 100 μm to 10 mm (see column 2, lines 42-44) (see instant claim 17) and a particle size distribution (i.e. granulometry) wherein about 28% of the particles have a size of between 500 μm to 1mm and about 56% of the particles have a particle size of between 2-6 mm (see column 2, lines 49-57) (see instant claim 1). It is taught that by providing such a particle size distribution, the composition exhibits excellent mechanical stability and is able to cement into healthy bone tissue in a similar manner to a bridge pile sunk into a gavel aggregate. See MPEP 2144.05(II)(A) which states that where the general conditions of a claim are described by the prior art, identifying optimum or workable ranges by routine experimentation is not considered inventive. Thus, modulating the particle size distribution of the bioglass of Santos, like that described by Gilchrist, would have been an obvious parameter to manipulate so as to identify a distribution that would yield the best osteogenic outcome. If such manipulation resulted in a distribution overlapping with that claimed, such a result would have been a product of ordinary skill and common sense, not one of innovation. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 1 is rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor. Claim 1 recites, “… the microporous size ranges from 50um to 600m, from 2006-600um, and the microporous size ranges from 550 nm to 2 um, of 550nm to 1.5 um…”. There appears to be multiple limitations in regards to both of the the microporous and microporous size ranges and it is not clear what is limiting/required. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP 2173.05(c). The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Sep 14, 2022
Application Filed
Aug 19, 2025
Non-Final Rejection mailed — §103, §112
Nov 19, 2025
Response Filed
Dec 10, 2025
Final Rejection mailed — §103, §112
Mar 09, 2026
Request for Continued Examination
Mar 16, 2026
Response after Non-Final Action
Sep 14, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778134
COMPOSTABLE ANTI-MICROBIAL FILM AND METHOD OF APPLYING FILM TO PACKAGING
4y 2m to grant Granted Nov 03, 2026
Patent 12779008
PROCESS FOR PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Patent 12767635
LIPOXYGENASE INHIBITORS
4y 1m to grant Granted Oct 20, 2026
Patent 12765549
METHOD OF USING/APPLYING A KERATIN HYDROLYSIS PEPTIDE SOLUTION TO PROMOTE TOLERANCE OF SOYBEAN AND ITS GROWTH UNDER STRESS OF FLOODING
2y 5m to grant Granted Oct 20, 2026
Patent 12758677
MATERIALS AND METHODS FOR DEODORIZATION OF MAMMALIAN URINE
2y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.7%)
4y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1002 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month